Arcellx (ACLX) Receivables - Net (2022 - 2023)

Name: Arcellx (ACLX) Receivables - Net (2022 - 2023) | Business Quant
Creator: Business Quant

Arcellx's quarterly Receivables - Net came in at $5.4 million in Q3 2023, down 81.47% quarter-over-quarter from $29.4 million in Q2 2023.

Arcellx has reported Receivables - Net for 2 years, with the latest figure at $5.4 million in Q3 2023.

For the quarter ending Q3 2023, Receivables - Net changed N/A year-over-year to $5.4 million; the trailing twelve-month figure through Sep 2023 stood at $5.4 million (changed N/A YoY), and the FY2022 full-year result was $2.0 million, changed N/A from the prior year.
Receivables - Net for Q3 2023 stood at $5.4 million, down from $29.4 million in the prior quarter.
The five-year high for Receivables - Net was $29.4 million in Q2 2023, with the low at $1.2 million in Q1 2023.

Peer Comparison

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Quantum Biopharma	961,148.99 Bn	961,148.98 Bn	-
2	Alterity Therapeutics	744,933.29 Bn	744,933.26 Bn	-
3	Legend Biotech	2,540.00 Bn	2,539.71 Bn	242.10 Mn
4	Nanobiotix	2,199.85 Bn	2,199.78 Bn	-
5	Akari Therapeutics	1,635.88 Bn	1,635.88 Bn	-
6	Vertex Pharmaceuticals	111.32 Bn	104.07 Bn	2.59 Bn
7	Evaxion A	62.56 Bn	62.54 Bn	-
8	Regeneron Pharmaceuticals	62.55 Bn	53.79 Bn	3.31 Bn
9	Alnylam Pharmaceuticals	39.57 Bn	36.56 Bn	959.66 Mn
10	Arcellx	6.48 Bn	6.48 Bn	-

Download Data 🔒